Investors

Investors 2018-02-05T09:29:16+00:00

Dimerix is discovering and developing important new drug therapies for major unmet medical needs identified using our proprietary cell-based drug discovery platform.

At the same time, our transformative drug discovery technology, known as Receptor-HIT, provides Dimerix with ongoing revenues from global industry partners seeking to improve their own programs.

Our vision is to positively improve human health through the creation of new treatments for major unmet medical needs.

Latest ASX Announcements

Analyst coverage: Updated NDF Research note

NDF Research have updated their coverage note titled "Dimerix - DMX-200's credibility increases" The report is available here.

ASX: Chief Medical Officer appointment and trial update

Dimerix is pleased to announce the appointment of Associate Professor David Packham to the role of Chief Medical Officer (CMO), and has provided an update on the development plan for its lead therapeutic program DMX-200 for [...]

ASX: Dimerix on Channel 7 News

Dimerix's DMX-200 clinical program has been featured on Channel 7 News. Full details are available here. The video is available on the Channel 7 website here.

ASX announcement: Dimerix raises a further A$4.5M

Dimerix Limited  has raised an additional $4.5 million through the issue of 37,500,000 shares at 12 cents per share to wholesale and institutional clients of Westar Capital and Baker Young Stockbrokers who acted as Joint [...]

Read More

Media Coverage

Analyst coverage: Updated NDF Research note

NDF Research have updated their coverage note titled "Dimerix - DMX-200's credibility increases" The report is available here.

ASX: Chief Medical Officer appointment and trial update

Dimerix is pleased to announce the appointment of Associate Professor David Packham to the role of Chief Medical Officer (CMO), and has provided an update on the development plan for its lead therapeutic program DMX-200 for [...]

ASX: Dimerix on Channel 7 News

Dimerix's DMX-200 clinical program has been featured on Channel 7 News. Full details are available here. The video is available on the Channel 7 website here.

Dimerix clinical studies in the media

Dimerix is pleased to announce coverage of our DMX-200 clinical program in the media. In support of Kidney Week 2018, Channel 7 reported on DMX-200 for patients with kidney disease. Follow the link for the [...]

Read More

Analyst Reports

Analyst coverage: Updated NDF Research note

NDF Research have updated their coverage note titled "Dimerix - DMX-200's credibility increases" The report is available here.

Baker Young DXB Flash Note November 2017

Read this here. 

Bioshares November 2017

View their report here. 

ASX Announcements – Baker Young Initiates Coverage of DXB

Baker Young Stockbrokers have initiated coverage of Dimerix Limited. The research report is available here: BY-DXB Research Report - Oct - Initiation of Coverage - BUY.

Read More

Stock Quote

View stock price: ASX Stock Price

Corporate Fact Sheet

Most recent fact sheet: February 2018

Email Alert

subscribe to news updates